WLLW — Willow Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- CA$5.07m
- CA$5.63m
- CA$4.66m
Annual cashflow statement for Willow Biosciences, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | C2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -33.9 | -6.14 | -14.8 | -13 | -6.19 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 18.2 | -15 | -1.82 | 0.421 | 0.324 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.211 | -0.316 | 0.129 | -0.207 | 0.756 |
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -12.8 | -18.2 | -13.9 | -11 | -3.72 |
| Capital Expenditures | -0.997 | -1.77 | -0.682 | -0.619 | -0.02 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.16 | 0.092 | -3.87 | 4.08 | 0.098 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Sale of Intangible Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.837 | -1.67 | -4.55 | 3.46 | 0.078 |
| Financing Cash Flow Items | 0.025 | -0.002 | 0 | -0.042 | -0.266 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 9.89 | 34.1 | -0.723 | -0.254 | 0.786 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -3.75 | 14.2 | -19.1 | -7.86 | -2.81 |